rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

NovoCure Limited -

NVCR · Nasdaq

Health CareMedical DevicesNot moving yet

NVCR stood above a rising 150-day average in 21 of the last 52 weekly readings, and has been out of that trend for the last 3 weeks. It is 9.1% below that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−9 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 3
Industry in uptrend
27% -9 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$6.5M
Officials’ trades on record
3
Institutions holding
205 (-3)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 21 of 52 weeks.

17 Apr – 16 Oct
19%29%40%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$3.9M$0$815KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

3 disclosed lines: House 3, Senate 0, executive 0; 2 people.

WhoDidAmountTraded
Marie Newman House: U.S. House ClerkIL03boughtspouse$15k–$50k2 Jul 2021filed 5 Aug 2021
Donna E. Shalala House: U.S. House ClerkFL27sold$1k–$15k24 Jun 2019filed 27 Apr 2020
Donna E. Shalala House: U.S. House ClerkFL27bought$1k–$15k19 Jun 2019filed 27 Apr 2020

Insiders

Buy orders, 12 months0
Sale orders, 12 months24
Buyers · sellers0 · 14
WhoDidSharesTraded
Frank X. LeonardChief Executive Officersold34,273at $17.934 Jun 2026filed 5 Jun 2026
Jeryl L. HillemanDirectorsold2,945at $15.772 Jun 2026filed 3 Jun 2026
Gabriel LeungDirectorsold2,945at $15.772 Jun 2026filed 3 Jun 2026
David HungDirectorsold2,945at $15.772 Jun 2026filed 3 Jun 2026
W. Anthony VernonDirectorsold2,945at $15.772 Jun 2026filed 3 Jun 2026
Timothy J. ScannellDirectorsold2,945at $15.772 Jun 2026filed 3 Jun 2026
Allyson J. OceanDirectorsold2,945at $15.772 Jun 2026filed 3 Jun 2026
Kristin StaffordDirectorsold2,945at $15.772 Jun 2026filed 3 Jun 2026
Mukund ParavasthuChief Operating Officersold43,246at $13.775 Mar 2026filed 5 Mar 2026
Uri WeinbergChf Medical and Innovation Ofrsold6,412at $13.314 Mar 2026filed 5 Mar 2026
Frank X. LeonardChief Executive Officersold5,607at $13.314 Mar 2026filed 5 Mar 2026
Michal Nath PuriChief Human Resources Officersold1,100at $13.314 Mar 2026filed 5 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders205-3 on the quarter
New · exited33 · 38
Reported value$1.6B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
FMR LLCadded · filed 13 Aug 202617,373,078$263.2M+303,929+1.8%
BlackRock, Inc.added · filed 7 Aug 202613,413,699$203.2M+219,934+1.7%
Soleus Capital Management, L.P.reduced · filed 11 Aug 20269,913,401$150.2M-578,990−5.5%
VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 20266,272,490$95.0M+20,789+0.3%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20264,903,633$74.3M+221,569+4.7%
MORGAN STANLEYreduced · filed 13 Aug 20264,522,389$68.5M-19,137−0.4%
STATE STREET CORPadded · filed 7 Aug 20262,866,546$43.4M+304,729+11.9%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 20262,798,351$42.4M+286,644+11.4%
WELLS FARGO & COMPANYreduced · filed 14 Aug 20262,528,093$38.3M-423,144−14.3%
Quantinno Capital Management LPreduced · filed 13 Aug 20262,223,455$33.7M-263,921−10.6%
31 Mar 2023 – 30 Jun 2026
189214238Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Arye Barak Ben Company insiderGeneral Counsel · last 30 Jun 20260 · 0
Asaf Danziger Company insiderDirector · last 30 Jun 20262 · 55
Frank X. Leonard Company insiderChief Executive Officer · last 30 Jun 20260 · 41
Michal Nath Puri Company insiderChief Human Resources Officer · last 30 Jun 20260 · 5
Allyson J. Ocean Company insiderDirector · last 3 Jun 20260 · 2
David Hung Company insiderDirector · last 3 Jun 20260 · 2
Gabriel Leung Company insiderDirector · last 3 Jun 20260 · 40
Jeryl L. Hilleman Company insiderDirector · last 3 Jun 20260 · 4
Kristin Stafford Company insiderDirector · last 3 Jun 20260 · 2
Martin J. Madden Company insiderDirector · last 3 Jun 20260 · 2
Timothy J. Scannell Company insiderDirector · last 3 Jun 20260 · 3
W. Anthony Vernon Company insiderDirector · last 3 Jun 20260 · 4

Same industry

RCEL Avita MedicalLeading+100%
ATRC AtriCureLeading+49%
HAE HaemoneticsLeading+48%
HTFL HeartflowLeading+40%

Distance from each stock’s own 150-day average.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202574.5%
Operating profit marginFY 2025 · to 31 Dec 2025-23.5%
Free cash flow marginFY 2025 · to 31 Dec 2025-11.5%
Return on capital employedFY 2025 · to 31 Dec 2025-26.5%
Debt to equityFY 2025 · to 31 Dec 20250.57×
Interest coverFY 2025 · to 31 Dec 2025-6.92×
Research spendFY 2025 · to 31 Dec 202534.3%
Share count trendFY 2025 · to 20 Feb 20261.2%
Cash and equivalentsFY 2025 · to 31 Dec 2025$93.5M
Free cash flowFY 2025 · to 31 Dec 2025−$75.7M

Analyst forecasts

No analyst forecasts yet.